Lonza launches 2013-2014 BioResearch Catalog

Lonza Launches 2013-2014 BioResearch Catalog:
Solutions for Accelerating Drug Development for Diabetes

Diabetes prevention has become a key focus area for the drug development market. The disease currently affects 366 million people worldwide and is expected to affect 552 million by 2030. With the prevalence of diabetes growing globally, the availability of primary human cells from diabetic donors is critical to increase research and knowledge about the disease at a cellular level. A solution to avoid roadblocks in diabetes research is using Clonetics™ Fresh Human Pancreatic Islets that are presented in Lonza’s new BioResearch Catalog. The full 2013-2014 catalog provides information on Primary Cells and Media, Mycoplasma Detection and Prevention, Transfection, BioAssay Products and Services, Electrophoresis and Analysis as well as QC Testing Solutions.
Customers may browse the Flash-Version of the entire BioResearch Catalog and explore their favorite products online, visiting www.lonza.com/catalog.
About Lonza Pharma – Bioscience
Lonza provides the pharma market with the tools life science researchers use to develop and test therapeutics, from basic research through to final product release. Lonza’s bioscience products and services range from cell culture and discovery technologies for research, to quality control tests and software to ensure product quality. Lonza Pharma – Bioscience serves research customers worldwide in pharmaceutical, biopharmaceutical, biotechnology and personal care companies, as well as academic and government research institutions. The company delivers physiologically relevant cell biology solutions, biomarker discovery services, technologies to understand compound action and complete solutions for rapid microbiology. Primary brands include BioWhittaker™, Clonetics™, FlashGel™, MetaPhor™, MycoAlert™, Nucleofection&t rade;, NuSieve™, PAGEr™, Poietics™ and SeaKem®.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange and secondary listed on the Singapore Exchange Securities Trading Limited (“SGX-ST”). In 2012, the company had sales of CHF 3.925 billion. Further information can be found at www.lonza.com.





Recent Issues